New pill shows promise in shrinking Hard-to-Treat breast tumors
NCT ID NCT06253195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors when used alone or with other cancer medicines. This is an early-phase trial, so the main focus was safety, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, 510245, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Can your own immune cells beat advanced cancer?
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple